title: Changes to the migratory inhibitory factor, IL-17, and IL-10 levels in serum from chronic hepatitis B patients and clinical significance following Baraclude(®) treatment.
abstract: This study aimed to determine the relationship between changes in the serum levels of macrophage migratory inhibitory factor (MIF), interleukin (IL) 17, and IL-10 during chronic hepatitis B treatment via Baraclude(®) (Bristol-Meyers Squibb). Thirty-six patients with chronic hepatitis B and 24 healthy individuals were selected as the experimental and control groups, respectively, and the serum levels of MIF, IL-17, and IL-10 were measured during the period in which the experimental group was treated with oral Baraclude(®); meanwhile, the alanine aminotransferase (ALT), hepatitis B virus (HBV) DNA, and HBV marker (M) levels were measured in the experimental group. In the experimental group, the ALT and HBV-DNA levels began to exhibit obvious decreases in week 4, and the MIF and IL-17 levels exhibited obvious increases in week 4 followed by gradual decreases; however, the IL-10 level exhibited an obvious decrease in week 12 and then increased gradually. These changes were significant when compared with the control group (P < 0.05). In conclusion, Baraclude(®) treatment not only actively suppressed HBV but also indirectly balanced the MIF, IL-17, and IL-10 levels and reduced the liver inflammatory response.
authors.affiliation: Gastroenterology Department of the General Hospital of Lanzhou in the Military District of Lanzhou, Lanzhou City, Gansu Province, China yuxiaohui_yxh@163.com.
authors.forename: X-H
authors.initials: XH
authors.lastname: Yu
authors.affiliation: Gastroenterology Department of the General Hospital of Lanzhou in the Military District of Lanzhou, Lanzhou City, Gansu Province, China.
authors.forename: J-C
authors.initials: JC
authors.lastname: Zhang
authors.affiliation: Gastroenterology Department of the General Hospital of Lanzhou in the Military District of Lanzhou, Lanzhou City, Gansu Province, China.
authors.forename: X-Y
authors.initials: XY
authors.lastname: Li
authors.affiliation: Analysis Department of the General Hospital of Lanzhou in the Military District of Lanzhou, Lanzhou City, Gansu Province, China.
authors.forename: T
authors.initials: T
authors.lastname: Chen
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D005260:Female; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D020381:Interleukin-17 / Q000097:blood*; D019746:Intramolecular Oxidoreductases / Q000097:blood*; D008263:Macrophage Migration-Inhibitory Factors / Q000097:blood*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; C508609:IL10 protein, human; D020381:Interleukin-17; D008263:Macrophage Migration-Inhibitory Factors; D016753:Interleukin-10; C413685:entecavir; D006147:Guanine; D000410:Alanine Transaminase; D019746:Intramolecular Oxidoreductases; C515598:MIF protein, human